Purpose: IMRT (intensity-modulated radiotherapy) verification techniques are reviewed together with investigations demonstrating the intrinsic verification problems. Material and Methods: Different IMRT verification procedures for either class solutions or individual patients are demonstrated. Among the latter are techniques like fluence or three-dimensional (3-D) dose distribution verification within a transfer phantom. Different radiographic films and absolute dose probes are investigated for their suitability. Finally, Monte Carlo techniques (XVMC/VEF) are used for error detection and IMRT verification. Results: During introduction of clinical IMRT for head and neck (H&N) tumors, we concurrently applied fluence, relative, and absolute dose measurement. While fluence and relative dose are in rather good agreement with calculations, absolute dose is always low when compared to the TPS (TMS 6.1A, Nucletron B.V.) by 5-7%. This deviation seems to depend not on the number of segments, but can strongly depend on MLC misalignment. Further investigations have revealed the importance of a detailed commissioning of the TPS down to the small-field range using diamond or diode probes and its detailed verification. In addition, simple tests have shown that dose calculation approximations in the IMRT option of TMS are one major source of the dose deviation. XVMC/VEF does not use such approximations.
Introduction
While IMRT (intensity-modulated radiotherapy) treatments of patients started some years ago in the USA, the introduction into clinical routine has proceeded much slower in Germany. In the meantime, some institutions have obtained experience in IMRT treatments, and a large community of radiation oncology departments are in the starting phases.
Many methods for small-field dosimetry in IMRT, such as those using different dosimeters like TLDs, semiconductor diodes, diamond detectors or ionization chambers with small volumes, have been tested (e.g. [19] ). Verification methods for use in clinical practice were recently published by Ezzell et al. [8] , MacKenzie et al. [23] , Rhein et al. [25] , and others. There is a critical review within a report of the IMRT Collaborative Working Group of the National Cancer Institute of the USA [5] , which contains a summary of IMRT verification methods and their problems.
The purpose of this paper is to give an overview of IMRT verification strategies and methods, demonstrated on head and neck (H&N) cancer cases. The investigations have revealed weak links in the entire chain of therapy planning system (TPS) commissioning -treatment planning -deliveryverification and yield a critical assessment of what can be used to minimize errors in IMRT dose delivery. Finally, we derive a verification procedure, which seems reliable and practicable.
Material and Methods

IMRT Method
The treatment of H&N cancers by means of IMRT was started in 2002, using a seven-beam technique equally spaced in the posterior hemisphere according to Hunt et al. [16] with gantry angles from 90°to 270°in 30°steps. A conventional anterior supraclavicular field is then added caudal to the IMRT part by means of a half-beam technique. This additional field is not included in the fluence optimization but in the weight optimization to prevent under-or overdosage in the junction area (see Figure 6 ). For optimization, an extended planning target volume (EPTV) is used, defined by the application of an isotropic margin of 0.5 cm around the PTV. On the other hand, the mean dose in the PTV is normalized to 100%. One or both parotid glands, the spinal cord, the brain stem, and the unspecified tissue outside the EPTV plus OARs (organs at risk) are included in the optimization as OARs. Spinal cord and brain stem are extended by an isotropic safety margin of 0.7 cm. In the objective function, dose-volume constraints are applied to all OARs. Two separate treatment protocols are under investigation. One applies a sequential boost technique with the same seven-field IMRT technique used in the preceding large-volume IMRT treatment (the latter being shown in Figure 6 ). The other one makes use of a simultaneous integrated boost (SIB) technique, as described by Wu et al. [31] . A precise patient setup is achieved by means of a stereotactic localization technique (H&N mask system, BrainLAB ® ).
IMRT Verification Strategies
Since IMRT is a sophisticated task for treatment planning as well as for realization of the treatment, a reliable quality assurance (QA) of the dose distribution within the patient is of extraordinary importance. The authors of the aforementioned report [5] stress that IMRT dose distributions are characterized by complex three-dimensional (3-D) dose gradients and a time-dependent fluence delivery, placing severe limitations on the dosimeters and techniques. They claim that, even today, the ionization chamber is a benchmark probe for IMRT dosepoint measurements. Additionally, radiographic film dosimetry is the tool of choice for 2-D dosimetry, taking into account that even relative dosimetry is a difficult task.
The clinical implementation of IMRT in H&N tumor treatment revealed a variety of problems. First of all, dose calculation by means of pencil beam model with IMRT-specific approximations and disregarding small-field problems [1] (Ahnesjö 2002, personal communication; Murman 2003, personal communication) is possibly too inaccurate to achieve reliable results in an inhomogeneous medium in case of very small fields or field segments, which results from a high-resolution fluence segmentation. Deficiency in lateral scatter calculation algorithms leads not only to a systematic error, but also to a convergence error [17] . The latter originates from the reaction of the optimization process to dose errors by compensating them in an erroneous modification of the fluence distributions.
Another issue regarding the accuracy of treatment planning systems is the inappropriate modeling of treatment head details, which, in fact, turns out to strongly influence the accuracy of output factors and beam profiles in case of small irregular fields, especially in off-axis positions. It seems that the requirements for commissioning of IMRT should be similar to the process used in stereotactic radiosurgery. Commissioning data set must be carefully examined, if the requirements for IMRT are met. The profiles should be measured with suited detectors, like microchamber, diode or diamonds. Output factors should be measured down to the smallest possible segment size. Simple multileaf modulated beams should be generated and the absolute dose verified in a slab phantom. These subbeams should be calculated as single fields as well, because different algorithms are often used for modulated as opposed to unmodulated beams.
These are some reasons why careful and multiple verification methods of IMRT treatment plans must be done to try to separate the different sources of inaccuracies and to correlate them to TPS, verification-or delivery-associated problems. From such a study, reliable verification techniques can presumably be derived, and the remaining TPS-associated errors can be explained and regarded for corrections.
IMRT plan verification would require, in principle, an inhomogeneous anthropomorphic phantom identical to the patient. A realistic solution of the problem could be a separation of the problem into a two-step procedure, starting a new treat- 
Verification of Class Solutions
A classic method for verification of class solutions is the application of the treatment technique to a RANDO ® phantom and applying TLDs, in combination with radiographic film dosimetry, to it (e.g., [23] [12, 26] , they offer one severe disadvantage. Steep dose gradients change with time due to ionic diffusion effects. Polymer gels, on the other hand, reveal the opposite behavior, because they are too sensitive to oxygen to be used as active measuring gels for lungs. On the other hand, diffusion is not an issue for this gel family [6] . In spite of this, very promising research on so-called normoxic polymer gels will make ideal 3-D gel dosimeters available in future.
Another technique of dose verification is becoming interesting, as computer hardware gets more and more powerful: the Monte Carlo (MC) dose simulation [15, 20, 22] . MC techniques are said to be the most precise dose engines, because, in principle, their accuracy depends only on the number of photons sampled [9] . A remaining problem is, as in the case of convolution-based algorithms, the necessity of a very detailed treatment head model and its commissioning in order to correctly describe output factors and beam profiles of small irregular fields. Once having benchmarked an MC code, this method will be perhaps the most reliable technique for class solution dose verification in the future.
Verification of Individual Patient Plans
Verification of treatment plans, individually for each patient, can basically be done by two different methods. The possibly easier way consists of the measurement of the fluence distribution separately for each modulated treatment field, but the Task Group report [5] stresses that "as no mechanism currently exists for independently verifying that the delivered fluence yields the desired dose distribution, an independent determination of the measured and calculated dose distribution coordinates is essential". In any case, even after succeeding to prove that it is sufficient to verify the fluence distributions of all fields, an absolute dose determination in at least one suitable point within a smoothly modulated area of each field by ionization chamber (IC) dosimetry or another reliable probe is mandatory. Because of the remaining inaccuracies of the TPS, described above, comparisons of these point doses with the correlated calculated doses must be regarded within an accuracy evaluation concept.
Moreover, as pointed out by the Task Group report, the calculated dose distribution must be accessed by an appropriate measurement. The only way to do this consists of a transfer of the optimized treatment plan to an easily accessible water equivalent or inhomogeneous phantom (transfer phantom). The shape and size of this phantom should be somewhat correlated with the shape of the treated area of the patient. This can be, in case of H&N tumors, a solid water cylinder with a diameter of approximately 20 cm. Such a phantom is easily accessible to dosimetry by radiographic films and absolute dose measurements by suitable probes for dose comparisons with calculated data (Figure 1) . A still open question is, however, how sensitive calculation errors arising from the incorrectly handled lateral scatter components by the TPS can be detected in a homogeneous phantom.
Dosimeters, Phantoms, and Evaluation Tools for IMRT Verification
As a simple TPS IMRT commissioning test, we used nine equally weighted non-overlapping 3 ϫ 3 cm 2 subfields to build a 9 ϫ 9 cm 2 field. The dose was then measured with 0.3 cm 3 IC (M23332, PTW), diamond (M60003, PTW), and dosimetry diode (M60008, PTW) in a slab phantom (RW3, PTW) at the isocenter in 10 cm depth. The test case was planned as a modulated beam with 1 Gy in the isocenter. Additionally, the example was calculated as one plan with nine single unmodulated fields.
Radiographic film dosimetry seems to be an easy task, but actually, it has to be done with extreme care. One of the reasons is that most film materials, which are not water-equivalent, are very sensitive to low-energy photons, produced in the process of depth penetration of a photon. Film dosimetry is, in principle, suitable for both verification methods described above.
Measurements of fluence distributions by means of film dosimetry are usually done in a water-equivalent slab phantom in a distinct depth, with the beam direction perpendicular to the plane of the film. The measurement within a phantom beyond the depth dose maximum as opposed to in-air measurements seems to be mandatory. Reasons are that the contributions of contaminant electrons and low-energy photons are not guaranteed to be constant and minor for all cases. In addition, the optical density of the film after irradiation only correlates with the dose, which itself is only proportional to the photon fluence, when a local secondary electron equilibrium exists [18] . Yet, comparisons of in-air and in-phantom investigations of fluence distributions, measured by means of a radiographic film (EDR2, Kodak), reveal only a minor difference in the order of < 2%. For this kind of investigation, with perpendicular beam entrance to film plane, the choice of film type is not really essential, as long as one properly corrects the dependence of the optical density to the dose. In Figure 2 , the results of four different radiographic films (Kodak X-OMAT, Kodak EC-V, CEA TVS, and Kodak EDR2) are presented. With the exception of the X-OMAT film, all reveal a relatively high linear response, but using a nonlinear fit procedure makes almost all of them suitable, depending on the desired dose range. The CEA TVS film is suitable only up to 0.5 Gy. Additional investigations on the EDR2 film dose-response curves from different phantom depths, shown in Figure 3 , reveal no real dependence, but can be attributed to differences in film processing. A similar shift can be observed in a longterm investigation of dose-response curves in a phantom in constant depth. This effect is corrected during dose determination.
The situation changes completely when applying film dosimetry to 3-D dose investigations within a transfer phantom, because, in coplanar IMRT techniques, all beam angles are parallel to the plane of the film. It is well known that in such a situation low-energy photons, increasingly produced with increased depth, result in a higher response of the film, such leading to dose errors of up to 20%. In an earlier study, we have investigated filter methods for parallel beam angles by use of a 0.6 mm thick lead filter, positioned symmetrically 5 mm from the film within the water-equivalent slab phantom, such yielding fairly good agreement within 7% with ionization chamber curves in the range > 1.5 cm. On the other hand, much better agreement without any filter at all is shown by the EDR2 film, in the depth range of 1-18 cm with a dose deviation to ionization chamber measurement < 4% (Figure 4) . Additionally, EDR2 can be used as an absolute dosimeter within an accuracy of about ± 3%. Similar to the procedure of Rhein et al. [25] , we apply a five-step dose calibration (0.5, …, 4.5 Gy), applied with field sizes of 5 ϫ 3 cm in 5 cm depth of RW3 within one autosequence of the record & verify (R&V) system Primeview & Lantis (Siemens) that exposes all fields to one film. It is important, during the corresponding ionization chamber measurement, to apply the complete sequence for the measurement of each individual subfield to account for scatter contributions from the remaining fields. As film and/or film processing changes with time, it is important to integrate the film calibration procedure into every film dosimetric investigation. The calibration procedure includes a nonlinear fit of the optical density versus dose data. One remaining question is whether any field size dependence influences the determination of dose distributions by means of EDR2 film dosimetry. For this reason, we investigated the output factor variation with field size by means of EDR2 film dosimetry, measured in a depth of 5 cm RW3, and compared it to ion- Figure 5 , revealing a slight difference in OF of up to 2% in the quadratic field size range of 2-20 cm, which makes EDR2 film dosimetry still suitable for IMRT verification in agreement with several other investigators (e.g., [7, 32] ).
Determination of the absolute dose in a dose reference point by means of ionization chamber dosimetry was done using a 0.3 cm 3 thimble chamber (M23332/Unidos, PTW). Absolute dosimetry in IMRT verification is under discussion because of the necessity of spatial positioning with high precision for comparisons with treatment plans. As IMRT plans normally show a larger dose inhomogeneity than 3-D CRT plans, dose gradients can be high across modulation sizes down to 1 ϫ 1 cm 2 . To avoid volume effects due to inhomogeneity of the dose distribution, many authors suggest using chambers with small volumes. For our own investigations, we defined a cylindrical volume of interest (VOI) in a highly homogeneous region of the dose cube with an appropriate size to account for chamber volume and setup errors. Thus, we rid ourselves of the necessity to position a very small volume probe with highest precision.
MR gel dosimetry is another new field under investigation for IMRT verification purposes, as described above. This is not only for class solution verifications, but also for individual dosimetry within a transfer phantom. The method is, in principle, capable of delivering a true 3-D dose distribution within any phantom shape, filled with a homogeneous polymer gel, such avoiding the danger of undetected hot or cold spots (e.g., [6, 12] ).
Finally, the use of MC simulation for verification purposes, as described above, can be just as valuable for individual patient verification as for class solutions. But, of course, a code must be found, which is quick and precise enough to deliver treatment plans for verification purpose within a reasonable time frame. We use XVMC, including the Monte Carlo (MC) treatment head model VEF, as described by Fippel et al. [9] [10] [11] , which we commissioned with data from our linac (Primus, Siemens) for 6-MV photons. The MC code is integrated into our inverse MC optimization programs, called IMCO ++ /IKO, described by Hartmann et al. [13, 14] . For verification purposes, the optimization is switched off, and XVMC/VEF is used for forward calculations of all beam segments, as determined by the pencil beam-based IMRT treatment plan (TMS, Nucletron B.V.) and transferred via DICOM-RT.
Finally, all verification work requires the comparison of calculations with measurements of fluence in a slab phantom or dose distributions in a suitable transfer phantom. To be highly flexible in redefining evaluation goals, we have developed our own verification software (IMRT-verif) by means of Matlab ® (MathWorks) similar to others [29] . It accepts data in the DICOM-RT standard, using fiducial points (Figure 1) for matching, tilting, and rescaling picture resolution and normalization of pixel contents, etc. The evaluation procedure delivers a comparison of the processed raw data, its absolute and relative dose difference, and, additionally, a modified plot of absolute gamma values [21] , with arrows per pixel indicating the direction and size of distance-to-agreement deviation. 
Abbildung 4. Tiefendosiskurven mit EDR2-Filmdosimetrie versus Ionisationskammer (oben). Dosisdifferenzen zwischen der Ionisationskammer und EDR2 (unten).
Results
When starting with IMRT treatment of patients in our clinics in 2002, we preferred to use different and independent verification methods to reveal any possible sources of error. So we have applied EDR2 film fluence verification for the modulated beams. Figure 7 shows the result of a comparison between the measured and calculated fluence-proportional profiles of one modulated beam of the treatment plan, shown in Figure 6 . It is composed of ten segments of a sevenbeam IMRT plan, with altogether 70 segments, applied to a slab phantom in 5 cm depth.
As a second method, the verification using a cylindrical transfer phantom (Figure 1 ), as described above, was applied routinely to every IMRT patient plan. At first, an absolute dose determination in one point of the transfer phantom, using IC or diode dosimetry, was done, yielding a measured dose about 5-7% too low in all cases investigated so far. This absolute dose value was used to correct the monitor units of all segments in the further relative dosimetry investigation. In Figure 8a , the result of the evaluation of one of five axial EDR2 verification films is shown, calibrated to absolute dose. The evaluation of the differences in this slice to TMS calculation in terms of relative dose difference ( Figure 8b ) and gamma plot (Figure 8c ) with a distance of agreement of 3 mm and 3% of dose shows a relative good agreement, with the exception of edge effects and hot spots. The absolute dose correction factor has been applied to the monitor units (MUs) of the patient treatment plan, as well.
The evaluation of the verification of five patient treatment plans, three of which had been calculated with a sequential boost and two with an SIB technique [27, 31] , showed absolute dose deviations, which seemed to depend on the number of segments. In five IMRT plans with about 70 segments, we found deviations of -6% (± 1%), whereas two boost cases with 30 segments somehow resulted in lower deviations of -5% (± 1%). The external segmentation software IMfast (Siemens, [28] ) was used to investigate if any dependence of absolute dose deviation from the number of segments for the same treatment plan exists. Starting from a TMS calculation with the built-in segmentation algorithm switched off, the resulting fluence distribution was externally segmented by IMfast with different restrictions to the number of segments. These plans were then transferred to the transfer phantom, followed by a comparison of absolute dose measurement to calculation. A comparison of two plans with 95 (on average 13.5 per gantry angle) and 29 (4.1 per beam) segments yielded a measured underdosage of 7.1% and 5.7%. A simple example of nine non-overlapping segments each 3 ϫ 3 cm 2 composing a 9 ϫ 9 cm 2 field also showed a lower dose, when calculated as IMRT beam. The closer intercomparison of TMS 6.1A calculation as modulated rather than as "normal beams" revealed a 2.6-3.4% (for two "different" Siemens Primus linacs) dose error due to approximations made for IMRT beams. As a result, all these comparisons did not confirm a dependence of the dose difference on the total number of segments.
Large deviations can be found when investigating relative dose profiles normalized to 10 ϫ 10 cm Figure 9 , a small segment which fulfills the minimal requirements of TMS IMRT (aperture with > 9 cm 2 and more than two leaf pairs open) is investigated, yielding dose deviations up to 9% for the pin-point IC and 5% for EDR2, respectively, when compared to the diode as a reference probe. The calculation deviates up to 2.5% for PB and 5% for CC, respectively.
Small-field dosimetry on quadratic fields showed that TMS compares well with diamond measurements down to 2 ϫ 2 cm 2 ( Figure 10 ). At 1 ϫ 1 cm 2 , the TMS 6.1A result gives a 23% lower output when compared to the diamond probe.
Diode shows a 11% higher dose response, the 0.3 cm 3 ionization chamber is completely off due to the detector size. Another measurement revealed that a microionization chamber with steel electrode (pin point) showed about 15% less dose than diamond at 1.2 ϫ 1.2 cm 2 . Nucletron B.V. has improved the head model in TMS 6.1B, using our small-field data measured with a diamond detector. A TMS 6.1B test with smaller and slightly elliptic source sizes (diameter of 0.265 and 0.235 cm, respectively, compared to 0.48 cm in TMS 6.1A) showed that, even at 1 ϫ 1 cm 2 , the output can be accurately modeled. Application of the new model to a patient case for comparison with the old model, strongly supports that small-field problems play a minor role, but instead, it is additional dose calculation approximations, which are only applied in IMRT (Murman 2003, personal communication) , which seem to play the major role.
In investigating the origin of the absolute dose deviation, additional research was done to determine how MLC misalignment influences absolute dose. Since MLC tolerance tables allow a ± 2 mm deviation of the nominal leaf position, we looked for the differences in absolute dose of the 70-segment patient plan when adding or subtracting 2 mm to every leaf within every segment as a worst case by means of an MC calculation. In doing so, we could detect a rather high influence of leaf position errors on the mean dose of about 8% (low by smaller and high by larger aperture) between both extremes ( Figure 12) .
When regarding the time-consuming verification methods, the question arises if MC dose verification could be a serious alternative. In Figure 11 , a comparison of PB-based TMS IMRT and XVMC/VEF forward calculation of the TMS plan (treatment plan of Figure 6 ) is shown in terms of dose-volume histograms (DVHs). The evaluation demonstrates that MC calculation reveals dose differences, which must be attributed to the systematic and convergence errors [17] based on the PB approximations.
Discussion
A strategy for IMRT verification is presented and some of the methods proposed were applied to a real H&N IMRT treatment plan. The simultaneous application of relative fluence and dose verification in a transfer phantom in combination with absolute dose verification by IC or diode dosimetry is time-consuming, but it demonstrated its sensitivity for the detection of errors which can occur in the IMRT chain. Whereas the fluence distributions of the modulated beams and the relative dose are in general good agreement with the calculated ones, we revealed systematic deviations in the absolute dose at a reference point. Our search for the causes of these deviations can be divided into four parts: (1) Investigations of the probes used for the verification process showed clearly that for relative film dosimetry in a transfer phantom the EDR2 film is the only suitable one, whereas for relative fluence verification other films like X-OMAT, EC-V are good as well. Investigations on probes for small-field absolute dose measurements showed that diodes and diamond detectors are suitable. IC-measured doses must be compared with averages of a suitably sized VOI around the dose reference point, chosen within a homogeneous area of the target. EDR2 film should not be used for absolute dosimetry, because its precision is restricted to ± 3%, which is not high enough. (2) The penumbra structures of the narrow beamlets in the transfer phantom verification are broader in the TMS calculations when compared to EDR2, as can clearly be seen in Figure 8a . The reasons for this difference could be the poorer spatial resolution of the dose cube and/or an erroneously determined focal spot size of TMS. The commissioning data set consists of profiles using a 0.13-cm 3 IC and output factors down to minimal field sizes of 5 ϫ 5 cm 2 according to TMS recommendations in version TMS 6.1A. OFs for smaller fields are extrapolated due to missing da- ta. The focal spot size evaluation is based on the measurements of the 10 ϫ 10 cm 2 field, which is usually done with a medium-volume chamber, although a high-resolution detector would be required for this purpose. A new head model with elliptic source size (TMS 6.1B) commissioned by diamond-based OFs down to 1 ϫ 1 cm 2 yields a rather good agreement. High deviations could also be found in the investigation of extremely small irregular field sizes (but within TMS default IMRT settings) with respect to beam profiles and OFs, showing again the necessity to measure data down to smaller field sizes with suitable probes like diamond or diodes for TPS commissioning. (3) Our investigations strongly support that small-field problems play a minor role, but instead there are additional dose calculation approximations, which are only applied in IMRT (Murman 2003, personal communication) which seem to play the major role. The dose deviations between measurement and calculation in a reference point of the transfer phantom and a simple IMRT test case demonstrated the TMS difference for IMRT calculation. "Normal beams" are calculated in TMS with fluence step functioned at field edge plus source blurring merged into the pencil beam kernel shape. Segmented multileaf step-andshoot modulation fields are handled differently than "normal beams". The total fluence is calculated by summing all segments, step-functioned at each segments edge, not just at the total field edge. Accompanied by implementation errors in 6.0 and 6.1A, overblurring occurred, possibly leading to a difference in transmission modeling. Thus, increasing the number of segments could lead to the observed increase in dose difference. In OTP (Nucletron B.V.) the dose deviation vanishes, because all segments are calculated without further approximations. All suggested improvements in head modeling and TPS commissioning also hold true for XVMC/VEF. (4) Finally, our investigations on MLC misalignment within the allowed tolerance reveal a major impact in IMRT dose delivery. The errors can, in principle, be detected by the fluence verification, described above. In any case, it is recommended to spend more time in MLC QA instead of in individual patient QA [4] . In addition to the calibration of the leaves at gantry zero position, it should be checked whether the MLC alignment depends on the gantry angle or on the moving direction of the leaf. A misalignment of the MLC not only affects the absolute dose, but could also affect the position of the dose distribution. Both could result in overdosage of the OAR and too low dose in the PTV. The same holds true for a detailed QA of the isocenter position.
Realizing that special IMRT dose calculation approximations, treatment head modeling, and small-field dosimetry can offer a severe problem to IMRT TPS, including MC-based systems, special care must be taken in commissioning and verification, especially for small offaxis fields. It has to be emphasized that the manufacturer of a TPS must disclose all approximations of the IMRT algorithm, together with recommendations for base data measurement being sensi- tive to those. Moreover, he must provide for a very detailed pre-release commissioning of the TPS, together with his beta test sites, and supply the customer with the results of this. It must be sufficient for a hospital physicist to restrict himself to a post-release TPS commissioning, which only can be a subset.
In spite of the discussed problems, IMRT is a method to spare the organs at risk and to get a sufficient dose in the PTV in one session [24, 30] . The classic irradiation technique for H&N tumors, on the other hand, claims multiple fields with over-or underdosage at field matchlines of electron and photon fields and does not allow sparing the parotids. Another source of error, relativizing the problems discussed in that paper, originates from the uncertainty of positioning, even when using a stereotactic mask system.
Conclusion
The process of finding the most reliable verification process is perhaps close to its end. First, the TPS, with its approximations and small-field behavior, should be extensively verified after a detailed commissioning phase. Second, an intensive MLC QA should be routinely run. Then, as a minimal individual verification concept, one should be able to reduce the procedure to either fluence or dose verification, but in both cases an absolute dose determination should be included for safety reasons. Both methods are sensitive to detect delivery problems.
An MC system like XVMC/VEF is extremely useful as a tool to detect different sources of errors during the IMRT introduction phase of a distinct tumor site. Especially in the H&N or the mediastinum region, pronounced systematic and convergence errors [17] can occur using the PB model. On the other hand, an MC system cannot be a verification tool for a PB-based TPS, as dose differences are a priori to be expected. So the only way to avoid the well-known problems of PB algorithm is to use inverse MC systems like IMCO ++ /IKO [3] or Hyperion [2] for IMRT. These systems avoid systematic and convergence errors completely, and an absolute dose verification should be done only for safety. Delivery can be controlled by an extended MLC QA and the interlock system.
